Showing results (101-110 of 134) with videos related to
Sort By:
Pageof 14
Journal of Virology|December 3, 2010
Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virusAdalbert Krawczyk, Jürgen Krauss, Anna M Eis-Hübinger, et al.Plos Pathogens|January 7, 2014
Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infectionJia Liu, Ejuan Zhang, Zhiyong Ma, et al.Scientific Reports|May 22, 2015
TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infectionWeimin Wu, Kirsten K Dietze, Kathrin Gibbert, et al.Journal of Virology|December 28, 2007
Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck modelMengji Lu, Xin Yao, Yang Xu, et al.Journal of Virology|November 22, 2013
Novel Woodchuck Hepatitis Virus (WHV) transgene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteinsZhongji Meng, Zhiyong Ma, Ejuan Zhang, et al.Molecular Immunology|February 3, 2017
Molecular cloning, characterization and expression analysis of Tim-3 and Galectin-9 in the woodchuck modelYanan Liu, Junzhong Wang, Lu Wang, et al.Virology|December 3, 2014
Woodchuck hepatitis virus core antigen-based DNA and protein vaccines induce qualitatively different immune responses that affect T cell recall responses and antiviral effectsEjuan Zhang, Anna D Kosinska, Zhiyong Ma, et al.Hepatology (Baltimore, Md.)|May 27, 2015
Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing propertiesRajiv G Tawar, Che C Colpitts, Jörg Timm, et al.Plos One|July 12, 2014
Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodiesMilena Lange, Melanie Fiedler, Dorothea Bankwitz, et al.The Lancet. Gastroenterology & Hepatology|October 2, 2017
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialMichel Bazinet, Victor Pântea, Valentin Cebotarescu, et al.Pageof 14